Mycophenolate for stubborn stomach Purpura (HSP) in children
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial looks at whether mycophenolate mofetil can help children ages 3–18 who have Henoch-Schönlein purpura affecting the gut that does not improve with steroid treatment. It may help reduce serious stomach symptoms like severe belly pain, bleeding, or bowel problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 3 and 18 years old
- Have a confirmed diagnosis of HSP (Henoch-Schönlein purpura) with digestive (gut) symptoms
- Have “refractory” gut HSP—your symptoms did not respond to IV steroid treatment, or came back when steroids were being lowered
- A parent/guardian agrees to the study and signs consent
- Have no known allergy to mycophenolate mofetil (MMF)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at treatment strategies for children with IgA vasculitis (also called Henoch-Schönlein purpura) when it mainly affects the stomach and intestines and symptoms do not improve with standard steroid dosing. It may help find better ways to control the illness early and prevent serious complications.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This trial looks at whether leflunomide can calm Henoch-Schonlein purpura (a childhood rash condition) when the rash is hard to control. If standard treatments don’t stop new or worsening rash, this study may offer another option.
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
This trial is testing whether adding the drug mycophenolate after your stem cell transplant can improve the treatment of systemic sclerosis (scleroderma). It may help people who are already undergoing this transplant to have better outcomes.
This trial is testing whether the drug mycophenolate mofetil can help people whose IgA nephropathy hasn't improved with standard treatments. It aims to reduce protein in the urine and protect kidney function.
Hear when a new Henoch-Schönlein Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.